- Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
- Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
- Revance Announces Proposed Public Offering of Common Stock
- Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.01 |
---|---|
High | 3.12 |
Low | 2.92 |
Bid | 1.17 |
Offer | 3.10 |
Previous close | 2.92 |
Average volume | 2.98m |
---|---|
Shares outstanding | 104.45m |
Free float | 94.91m |
P/E (TTM) | -- |
Market cap | 304.99m USD |
EPS (TTM) | -3.61 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼